Off Patent
May 2027

Januvia

sitagliptin phosphate

Merck Sharp and Dohme LLC

Tablet (oral) · NDA 021995

Last listed protection ends
May 24, 2027

The FDA lists 1 patent for Januvia, and this is the day the last one ends. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Patent 7,326,708
    Claims the drug substance, the drug product and a use (U-802)
  2. Patent 7,326,708
    Pediatric extension: six more months